A COVID-19 Symptom, Exposure and Immune Response Registry
COVID-19 Study - A Primarily Prospective Observational Study of COVID-19 Clinical Characteristics and Acquired Immune Response Within the General Population
1 other identifier
observational
804
1 country
1
Brief Summary
This is a 6-month, 100% remote study that will collect a broad range of data that may provide insight into the COVID-19 global pandemic. Data collected will include participant medical histories, history of prior SARS-CoV-2 infection and exposure to known cases. On an ongoing basis data will be collected on new contacts with known cases, the presence of COVID-19 symptoms, including severity and outcome, and information on the immune system response to SARS-CoV-2 infection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 13, 2020
CompletedFirst Posted
Study publicly available on registry
April 16, 2020
CompletedStudy Start
First participant enrolled
May 29, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 21, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 21, 2021
CompletedMarch 4, 2022
March 1, 2022
10 months
April 13, 2020
March 2, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Registry Data
Compilation of registry data via regular self-reported questionnaires on symptoms (known to be associated with COVID-19 diagnosis including presence, severity, and duration using the Obvio-19 app.
6 months
Eligibility Criteria
Adults residing in the USA, regardless of past or current COVID-19 status
You may qualify if:
- Open to any adult individuals (18 years of age or older) permanently residing in the United States
- Have regular access to smartphone and internet sufficient to support registry demands
- Willing and able to follow the procedures of the study
- Willing and able to provide informed consent
You may not qualify if:
- Participants unable to understand the study protocol or provide informed consent
- Participants unable or unwilling to perform all requested study tasks
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ObvioHealthlead
Study Sites (1)
ObvioHealth
Orlando, Florida, 328017, United States
Related Publications (1)
Shah P, Magee K, Buccellato KH, Ismond M, Watson J. Real world data on cardiometabolic diseases in U.S. adults during the SARS-CoV-2 pandemic: a decentralized registry study. Cardiovasc Diabetol. 2022 Feb 14;21(1):24. doi: 10.1186/s12933-022-01462-3.
PMID: 35164745DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 13, 2020
First Posted
April 16, 2020
Study Start
May 29, 2020
Primary Completion
March 21, 2021
Study Completion
March 21, 2021
Last Updated
March 4, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share